ANGLE

ANGLE

The leading experts in cancer cell capture and analysis from liquid biopsies

Founded 1994

United Kingdom 165 employees Post-IPO Equity Total: $29.68M Biotechnology, Health Care +1

ANGLE, the leading experts in cancer cell capture and analysis from liquid biopsies, is a world-leading liquid biopsy company specializing in innovative circulating tumor cell (CTC) diagnostic solutions. ANGLE's FDA cleared and patent-protected circulating tumor cell (CTC) harvesting technology, the Parsortix® PC1 System, allows complete downstream analysis of the sample, including whole cell imaging and proteomic analysis, as well as full genomic and transcriptomic molecular analysis, using a simple blood sample. The company's commercial businesses focus on diagnostic products such as the Parsortix® system and associated consumables, as well as clinical services offered through GCP-compliant laboratories in the UK and the United States. These services encompass custom-made assay development and clinical trial testing for the pharmaceutical industry. With over 80 peer-reviewed publications demonstrating the performance of the Parsortix system, ANGLE stands as a pioneering force in the biotechnology and healthcare industries, striving to make a substantial impact in research, drug development, and clinical oncology. Founded in 1994 and headquartered in the United Kingdom, the company recently secured a noteworthy £9.30M post-IPO equity investment on 05 June 2024. For more information, visit www.angleplc.com.

Funding Stage	Amount	Investors	Date
Post IPO Equity	£9.30M	-	05 Jun 2024
Post IPO Equity	£20.13M	-	15 Jul 2022
Venture Round	$250.00K	-	27 Mar 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

£9.30M

05 Jun 2024

Post IPO Equity

£20.13M

15 Jul 2022

Venture Round

$250.00K

27 Mar 2015

FAQ About ANGLE

The leading experts in cancer cell capture and analysis from liquid biopsies

ANGLE was founded in 1994.

ANGLE is headquartered in United Kingdom.

ANGLE operates in Biotechnology, Health Care and Medical Devices. Its work centres on Liquid Biopsy, Circulating Tumor Cells, Medical Device Manufacturer and Microfluidics.

ANGLE has approximately 165 employees.

ANGLE has completed 3 funding rounds, raising a total of $29.68M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to ANGLE include Vortex Biosciences, Cellsway, SmartCatch, Capio Biosciences, RareCyte, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ANGLE and Vortex Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About ANGLE

Funding Rounds & Investors (3)

ANGLE Alternatives & Competitors

FAQ About ANGLE